

Subject: Update on Bicillin L-A Availability Following Pfizer Recall

Date: August 28, 2025

To: Clinical Partners and Public Health Colleagues

From: Oregon Health Authority, Public Health Division, HST Section

Dear Colleague,

This message provides an important update to our initial communication dated July 14, 2025, regarding the Pfizer recall of Bicillin L-A, the first-line treatment for syphilis. Pfizer recently released an [availability update letter](#) detailing the status of Bicillin inventory and plans for product distribution. Below are the key updates:

Bicillin L-A Inventory and Distribution

1. Customers are advised to **begin ordering** Bicillin L-A from their wholesalers.
2. Shipments began last week, but at a limited pace:
 - 2 mL (1.2 million unit) syringes: 35% of historical demand
 - 4 mL (2.4 million unit) syringes: 40% of historical demand
 - Pediatric 600,000 units/mL prefilled syringe is on track to return to market with next anticipated delivery in late October 2025.
3. Pfizer's [Medical Request Process](#) remains active for urgent needs when Bicillin is not locally available. This process ensures that inventory from Pfizer's distribution centers is prioritized for:
 - Patients with confirmed congenital syphilis

800 NE Oregon Street, Suite 1105, Portland OR 97232

Voice: 971-673-0153 | Fax: 971-673-0178

All relay calls accepted | www.healthoregon.org/tb

- Pregnant patients with syphilis
4. As product availability may change, the most up-to-date source of supply availability remains Pfizer's [Availability Report](#).

Guidance for Clinical Sites with Non-Recalled Bicillin L-A

As Bicillin availability begins to improve, we encourage clinics with non-recalled Bicillin L-A in stock to:

- Resume treatment for all patients with primary or secondary syphilis, the most infectious stages.
- Continue prioritizing pregnant patients with any stage of syphilis.

Other patients with syphilis may be treated with Bicillin at the clinic or provider's discretion. However, please be aware that expanding eligibility beyond these priority groups may lead to faster depletion of your current supply, and future delivery timelines remain uncertain.

We appreciate your continued efforts to ensure timely and equitable access to syphilis treatment during this period of limited supply. Please reach out with any questions or concerns.

Sincerely,

Pete P. Singson, MD

Pronouns: he/him/his

HIV/STD/TB Medical Director

OREGON HEALTH AUTHORITY

Public Health Division

Cell: 503-358-3377

Email: pete.p.singson@oha.oregon.gov



800 NE Oregon Street, Suite 1105, Portland OR 97232

Voice: 971-673-0153 | Fax: 971-673-0178

All relay calls accepted | www.healthoregon.org/tb